Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

21.51
-0.3800-1.74%
Volume:1.31M
Turnover:28.42M
Market Cap:2.44B
PE:-8.66
High:22.56
Open:22.15
Low:21.51
Close:21.89
52wk High:30.06
52wk Low:11.25
Shares:113.58M
Float Shares:108.11M
Volume Ratio:0.71
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:4.65
PE(LYR):-8.85

Loading ...

Immunome Flags Press Release on FDA Acceptance of Varegacestat NDA for Desmoid Tumors

Reuters
·
Jul 08

Immunome - Pdufa Target Action Date for Varegacestat Set for April 28, 2027

THOMSON REUTERS
·
Jul 08

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

THOMSON REUTERS
·
Jul 08

Immunome CMO Robert Lechleider Sells USD 1.27 Million in Common Shares

Reuters
·
Jul 08

Immunome Grants 344,000 Inducement Stock Options Priced at $21.49 Per Share

Reuters
·
Jul 08

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 08

Immunome Director Isaac Barchas Disposes of 201,050 Common Shares Worth $4.4 Million

Reuters
·
Jul 03

Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile

TIPRANKS
·
Jun 30

Immunome Chief Medical Officer Robert Lechleider Disposes of 55,000 Common Shares Worth $1.09 Million

Reuters
·
Jun 30

Immunome’s New Radiopharma Trial Puts IMNM on Early Oncology Watchlists

TIPRANKS
·
Jun 19

Immunome CFO Max Rosett disposes of 60,000 common shares worth $1.09 million

Reuters
·
Jun 18

Immunome shareholders reaffirm board, auditor and pay policies

TIPRANKS
·
Jun 13

Immunome shareholders elect three Class III directors at annual meeting

Reuters
·
Jun 13

Immunome (IMNM) Receives a Buy from Wedbush

TIPRANKS
·
Jun 13

Immunome Price Target Maintained With a $31.00/Share by Wedbush

Dow Jones
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)

TIPRANKS
·
Jun 12

Craig-Hallum Sticks to Its Buy Rating for Immunome (IMNM)

TIPRANKS
·
Jun 11

Immunome doses first patient in Phase 1 trial of IM-1617 solid-tumor ADC

Reuters
·
Jun 11

Immunome - Plans Ind Submission for IM-1340 in Mid-2026 and IM-1335 in Late 2026

THOMSON REUTERS
·
Jun 11

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients With Advanced Solid Tumors

THOMSON REUTERS
·
Jun 11